UK markets closed

Santhera Pharmaceuticals Holding AG (0QN1.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
9.21+1.81 (+24.51%)
At close: 05:09PM GMT

Santhera Pharmaceuticals Holding AG

Hohenrainstrasse 24
Pratteln 4133
41 61 906 89 50

Full-time employees45

Key executives

NameTitlePayExercisedYear born
Dr. Thomas Meier Ph.D.Founder & Chairman83.75kN/A1962
Mr. Dario EklundChief Executive Officer814.82kN/A1968
Mr. Andrew P. Smith CGMA, FCMAChief Financial OfficerN/AN/A1963
Mr. Oliver StrubExecutive VP, General Counsel & SecretaryN/AN/A1963
Mr. Günther Metz Ph.D.Head of Business Development & Executive VPN/AN/A1958
Mr. Shabir Hasham M.D.Chief Medical OfficerN/AN/AN/A
Ms. Stephanie Brown B.Sc., M.B.A.President of North AmericaN/AN/A1961
Mr. Marc SchraderHead of Technical Development & OperationsN/AN/AN/A
Ms. Eva KaliasHead of Investor Relations & CommunicationsN/AN/AN/A
Mr. Neville Kodkani M.D.Head of Global Marketing & Partner ManagementN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.


Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

Corporate governance

Santhera Pharmaceuticals Holding AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.